Simple blood and urine test could spot bladder cancer return

NCT ID NCT07441499

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study is testing a new liquid biopsy that uses blood and urine samples to help diagnose, monitor treatment, and predict recurrence in people with urothelial carcinoma (a type of bladder cancer). Researchers will enroll 300 participants and compare the liquid biopsy results with standard tissue biopsies. The goal is to see if this non-invasive test can reliably track cancer changes over time.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Multi-component liquid biopsy (blood and urine test)
What this could lead to
If successful, this could provide a non-invasive way to detect and monitor urothelial cancer, potentially reducing the need for repeated tissue biopsies.
What could go wrong
This is an early-stage diagnostic study, not a treatment trial. The test may not be accurate enough to replace standard biopsy, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The second hospital of Tianjin Medical University

    RECRUITING

    Tianjin, 300000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.